Grace Gombolay

Grace Gombolay

Auto-generated profile, based on publicly available information

Grace Gombolay

Emory University School of Medicine, Children’s Healthcare of Atlanta

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
MNMargherita Nosadini
Margherita Nosadini
TTThomas Terrence
Thomas Terrence
MEMichael Eyre
Michael Eyre
BABanu Anlar
Banu Anlar
TAThais Armangue
Thais Armangue
RDRussell C. Dale
Russell C. Dale
Objective To create an international consensus treatment recommendation for pediatric NMDA receptor antibody encephalitis (NMDARE). Methods After selection of a panel of 27 experts with representation from all continents, a 2-step Delphi method was adopted to develop consensus on relevant treatment regimens and statements, along with key definitions in pediatric NMDARE (disease severity, failure to improve, and relapse). Finally, an online face-to-face meeting was held to reach consensus (defined as ≥75% agreement). Results Corticosteroids are recommended in all children with NMDARE (pulsed IV preferred), with additional IV immunoglobulin or plasma exchange in severe patients. Prolonged first-line immunotherapy can be offered for up to 3–12 months (oral corticosteroids or monthly IV corticosteroids/immunoglobulin), dependent on disease severity. Second-line treatments are recommended for cases refractory to first-line therapies (rituximab preferred over cyclophosphamide) and should be considered about 2 weeks after first-line initiation. Further immunotherapies for refractory disease 1-3 months after second-line initiation include another second-line treatment (such as cyclophosphamide) and escalation to tocilizumab. Maintenance immune suppression beyond 6 months (such as rituximab redosing or mycophenolate mofetil) is generally not required, except for patients with a more severe course or prolonged impairments and hospitalization. For patients with relapsing disease, second-line and prolonged maintenance therapy should be considered. The treatment of NMDARE following herpes simplex encephalitis should be similar to idiopathic NMDARE. Broad guidance is provided for the total treatment duration (first line, second line, and maintenance), which is dictated by the severity and clinical course (i.e., median 3, 9 and 18 months in the best, average, and worst responders, respectively). Recommendations on the timing of oncologic searches are provided. Conclusion These international consensus recommendations for the management of pediatric NMDARE aim to standardize the treatment and provide practical guidance for clinicians, rather than absolute rules. A similar recommendation could be applicable to adult patients.

9 April 2024 in Annals of Neurology
Verified
Journal Article
Open access
VRVyanka Redenbaugh
Vyanka Redenbaugh
JFJames P. Fryer
James P. Fryer
LCLaura Cacciaguerra
Laura Cacciaguerra
JCJohn J. Chen
John J. Chen
TGTammy M. Greenwood
Tammy M. Greenwood
EFEoin P. Flanagan
Eoin P. Flanagan
Objective: The aim of this study was to assess the diagnostic utility of cerebrospinal fluid (CSF) myelin oligodendrocyte glycoprotein antibodies (MOG‐IgG) testing.Methods: We retrospectively identified patients for CSF MOG‐IgG testing from January 1, 1996, to May 1, 2023, at Mayo Clinic and other medical centers that sent CSF MOG‐IgG for testing including: controls, 282; serum MOG‐IgG positive MOG antibody‐associated disease (MOGAD), 74; serum MOG‐IgG negative high‐risk phenotypes, 73; serum false positive MOG‐IgG with alternative diagnoses, 18. A live cell‐based assay assessed CSF MOG‐IgG positivity (IgG‐binding‐index [IBI], ≥2.5) using multiple anti‐human secondary antibodies and end‐titers were calculated if sufficient sample volume. Correlation of CSF MOG‐IgG IBI and titer was assessed.Results: The pan‐IgG Fc‐specific secondary was optimal, yielding CSF MOG‐IgG sensitivity of 90% and specificity of 98% (Youden's index 0.88). CSF MOG‐IgG was positive in: 4/282 (1.4%) controls; 66/74 (89%) serum MOG‐IgG positive MOGAD patients; and 9/73 (12%) serum MOG‐IgG negative patients with high‐risk phenotypes. Serum negative but CSF positive MOG‐IgG accounted for 9/83 (11%) MOGAD patients, and all fulfilled 2023 MOGAD diagnostic criteria. Subgroup analysis of serum MOG‐IgG low‐positives revealed CSF MOG‐IgG positivity more in MOGAD (13/16[81%]) than other diseases with false positive serum MOG‐IgG (3/15[20%]) (p = 0.01). CSF MOG‐IgG IBI and CSF MOG‐IgG titer (both available in 29 samples) were correlated (Spearman's r = 0.64, p < 0.001).Interpretation: CSF MOG‐IgG testing has diagnostic utility in patients with a suspicious phenotype but negative serum MOG‐IgG, and those with low positive serum MOG‐IgG results and diagnostic uncertainty. These findings support a role for CSF MOG‐IgG testing in the appropriate clinical setting. ANN NEUROL 2024;96:34–45

13 January 2023 in Pediatric Neurology
Verified
Journal Article
Closed access
GGGrace Y. Gombolay
Grace Y. Gombolay
NGNakul Gopalan
Nakul Gopalan
ABAndrea Bernasconi
Andrea Bernasconi
RNRima Nabbout
Rima Nabbout
JMJonathan T. Megerian
Jonathan T. Megerian
MGMatthew C. Gombolay
Matthew C. Gombolay

2 May 2018 in Current Treatment Options in Neurology
Verified
Journal Article
Closed access
PDF file
GGGrace Y. Gombolay
Grace Y. Gombolay
TCTanuja Chitnis
Tanuja Chitnis

1 September 2021 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
GGGrace Y. Gombolay
Grace Y. Gombolay
JGJudith A. Gadde
Judith A. Gadde

5 April 2024 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
GGGrace Y. Gombolay
Grace Y. Gombolay
ASAndrew Silva
Andrew Silva
MSMariah Schrum
Mariah Schrum
NGNakul Gopalan
Nakul Gopalan
JHJamika Hallman‐Cooper
Jamika Hallman‐Cooper
MGMatthew C Gombolay
Matthew C Gombolay
Objective: Artificial intelligence (AI)‐based decision support systems (DSS) are utilized in medicine but underlying decision‐making processes are usually unknown. Explainable AI (xAI) techniques provide insight into DSS, but little is known on how to design xAI for clinicians. Here we investigate the impact of various xAI techniques on a clinician's interaction with an AI‐based DSS in decision‐making tasks as compared to a general population.Methods: We conducted a randomized, blinded study in which members of the Child Neurology Society and American Academy of Neurology were compared to a general population. Participants received recommendations from a DSS via a random assignment of an xAI intervention (decision tree, crowd sourced agreement, case‐based reasoning, probability scores, counterfactual reasoning, feature importance, templated language, and no explanations). Primary outcomes included test performance and perceived explainability, trust, and social competence of the DSS. Secondary outcomes included compliance, understandability, and agreement per question.Results: We had 81 neurology participants with 284 in the general population. Decision trees were perceived as the more explainable by the medical versus general population (P < 0.01) and as more explainable than probability scores within the medical population (P < 0.001). Increasing neurology experience and perceived explainability degraded performance (P = 0.0214). Performance was not predicted by xAI method but by perceived explainability.Interpretation: xAI methods have different impacts on a medical versus general population; thus, xAI is not uniformly beneficial, and there is no one‐size‐fits‐all approach. Further user‐centered xAI research targeting clinicians and to develop personalized DSS for clinicians is needed.